ArticleCureus2025
Evaluation of Serum GPR-120 Levels in Diabetic Patients With and Without Nephropathy: A Comparative Study on Lipid and Renal Parameters.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The roles of free-fatty acid receptors in the pathophysiology of renal disorders.The Journal of pharmacology and experimental therapeutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic nephropathy (DN) remains one of the main reasons for end-stage renal disease globally and is strongly related to adverse lipid profiles, oxidative stress, and chronic inflammation. The G-protein coupled receptor 120 (GPR-120), a protein implicated in lipid metabolism and anti-inflammatory pathways, has garnered recent attention as a possible diagnostic and prognostic biomarker reflecting both metabolic derangements and renal injury. However, its clinical importance in diabetic cohorts, particularly those with nephropathy, remains underexplored.
methodsWe performed a case-control study of 200 subjects (adults) with type 2 diabetes mellitus, subdivided into those without nephropathy (n=100) and those with nephropathy (n=100). All subjects underwent comprehensive biochemical profiling, such as fasting glucose, postprandial glucose, glycated hemoglobin (HbA1C), lipid indices (total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides, and oxidized LDL), renal characteristic checks (creatinine, cystatin C, microalbuminuria, estimated glomerular filtration rate (eGFR)), and serum GPR-120 analyzed via enzyme-linked immunosorbent assay. We compared GPR-120 levels across both groups and performed regression analysis to investigate how GPR-120 correlates with lipid parameters and renal markers.
resultsSubjects with nephropathy exhibited drastically lower GPR-120 concentrations (2.9 ± 0.8 ng/mL) compared to the ones without nephropathy (11.2 ± 4.5 ng/mL, p<0.001). Regression analysis revealed that HDL-C positively correlated with GPR-120 (p<0.001), while LDL-C, triglycerides, and cystatin C were negatively associated with GPR-120 (p<0.01). Microalbuminuria additionally showed an inverse relationship with GPR-120 levels. Considerably higher eGFR values predicted better GPR-120 concentrations, suggesting a defensive or compensatory mechanism.
conclusionOur findings indicate that GPR-120 is markedly reduced in DN and demonstrates strong associations with both adverse lipid profiles and renal dysfunction. The GPR-120 may represent an emerging biomarker of integrated metabolic and renal health in diabetes. Larger longitudinal studies are recommended to confirm its prognostic utility and clarify whether interventions targeting dyslipidemia could modulate GPR-120 levels.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.